• Women aged <50 years old • Stage 1, 2 or 3 invasive breast cancer • Have no distant metastases • Patients due to undergo neoadjuvant treatment should be approached before this starts
For those whose core biopsy shows DCIS only but post-excision biopsy pathology confirms invasive cancer, approach should be made as soon as possible following diagnosis and completion of the baseline questionnaire should be prior to the start of adjuvant treatment.
Exclusion:
• Confirmed diagnosis of CIS (ductal or lobular) only • Men
Non-Hodgkin Lymphoma
Inclusion:
• Any pathological diagnosis of Diffuse Large B Cell lymphoma (DLBCL) including;
o Secondary transforming or transformed DLBCL which has transformed from an indolent/low grade lymphoma (most commonly Follicular Lymphoma) as long as the low grade lymphoma was not treated and this is a recent transformation for which curative intent treatment has not yet started.
o Rare sub-types of DLBCL such as T cell rich Large B Cell Lymphoma and primary mediastinal (thymic) large B-cell lymphoma
Patients who have started steroid pre-phase treatment are eligible for approach before the start of chemotherapy.
Gynaecological cancers ALL GYNAECOLOGICAL CANCERS Gynaecological Cancer Exclusion criteria
Synchronous gynaecological primary cancers. For example, synchronous ovarian and endometrial primary cancers.
OVARIAN Ovarian Inclusion criteria:
Have a confirmed diagnosis either from cytology, histology, imaging or diagnostic primary surgery of either; Patients should be entered prior to any treatment including surgery. However, where the diagnosis is only made at the time of surgery, these women may enter the study following surgery. Approach should be made as soon as possible following diagnosis and completion of the baseline questionnaire should occur prior to the start of adjuvant treatment.
Ovarian Exclusion criteria:
• Borderline ovarian cancer
•

Germ cell tumour
• Sarcoma
ENDOMETRIAL Endometrial Inclusion criteria:
Have a confirmed diagnosis either from cytology, histology or imaging of;
• endometrial cancer
Patients should be entered prior to any treatment including surgery. However, where the diagnosis is only made at the time of surgery, these women may enter the study following surgery. Approach should be made as soon as possible following diagnosis and completion of the baseline questionnaire should occur prior to the start of adjuvant treatment. 
FIGO stage
Endometrial Exclusion criteria
• Choriocarcinoma
• Germ cell tumour
CERVICAL Cervical Inclusion criteria:
•
Cervical cancer
Cervical Exclusion criteria:
• FIGO stage IA1
• Cervical carcinoma in situ (CIS)
• Sarcoma 
